Rationale and Feasibility of Intranasal Delivery of Drugs to the Eustachian Tube Orifice
- 241 Downloads
Intranasal medication for eustachian tube dysfunction (ETD) is an established practice in otolaryngology through the effects of steroids, decongestants, antihistamines or a combination of the above in reducing tubal oedema. The author has previously argued that a double-blind, randomised control trial would be helpful in determining effectiveness of treatment, if a standardised head position, chiefly Mygind or Ragan, was adopted to maximise intranasal drop delivery into the eustachian tube orifice. One recent paper suggests that intranasal treatment is not very effective, but ultimately does not state whether a standardised head position was adopted. Although a large body of evidence supports the hypothesis that the nasal passages are the route to middle ear disease, there is as yet no paper that has been published that has specifically addressed this issue, therefore the author must conclude that evidence to support intranasal treatment for ETD is still lacking and further research is desirable.
KeywordsIntranasal drugs Eustachian tube orifice Eustachian tube dysfunction Intranasal administration Head position Delivery Rationale Feasibility Allergy Otitis media Suppurative otitis media Intranasal steroids Intranasal decongestants Intranasal antihistamines Intranasal saline
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 5.Elies W. Topical steroids in the treatment of mucosal swelling of the nasal cavity. J Chemother. 1997;6:31–4.Google Scholar
- 14.Kraemmer M, Marshaal S, Richardson M. Aetiological factors in the development of chronic middle ear effusions. Clinical Rev Allergy. 1984;2:319–28.Google Scholar
- 18.•• Karagama Y, Rashid M, Lancaster J, Karkanevatos A, William R. Intranasal delivery of drugs to eustachian tube orifice. J Laryngol Otol. 2011;125(9):934–9. This prospective five period cross-over study was published in 2011 and is the first to address the issue of optimal head position. It is postulated that the efficacy of intranasal delivery can only be ascertained if maximal delivery is achieved.PubMedCrossRefGoogle Scholar
- 19.Thomas C, Simpson S, Butler C, van der Voort J. Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children. Cochrane Database Syst Rev. 2006;3CD001935Google Scholar
- 21.•• Gluth M, McDonald D, Weaver A, Bauch C, Beatty C, Orvidas L. Management of eustachian tube dysfunction with nasal steroid spray: a prospective, randomized, placebo-controlled trial. Arch Otolaryngol Head Neck Surg. 2011;137(5):449–55. This randomized, placebo-controlled, double-blind prospective clinical trial was published in 2011 to determine the efficacy of intranasal steroids in treating the tympanometric signs and symptoms of eustachian tube dysfunction. No statistical difference was demonstrated between active and placebo arms.PubMedCrossRefGoogle Scholar
- 22.Jackson L, Light J, Rosenberg S, Silverstein H, Thompson J. Direct application of dexamethasone for the treatment of chronic eustachian tube dysfunction. ENT J. 2003;82(1).Google Scholar
- 27.Cantekin E, Mandel E, Bluestone C, Rockette H, Paradise J, Stool S, et al. Lack of efficacy of a decongestant-antihistamine combination for otitis media with effusion (“secretory” otitis media) in children: results of a double-blind, randomized trial. N Engl J Med. 1983;308(6):297–301.PubMedCrossRefGoogle Scholar